New hope for cancer pain in seniors with kidney disease?

NCT ID NCT07421674

Not yet recruiting Symptom relief Sponsor: Taian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether hydromorphone sustained-release tablets can safely relieve moderate to severe cancer pain in elderly patients who also have kidney issues. Researchers will compare these patients to those with normal kidney function, monitoring pain relief, kidney function, and side effects over 4 weeks. The goal is to find a better way to manage pain without harming the kidneys.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydromorphone sustained-release tablets
What this could lead to: If successful, this could provide a safer pain management option for elderly cancer patients with kidney issues, improving their quality of life.
What could go wrong: This is a small, early-stage study with only 62 participants, so results may not apply broadly. The drug may still cause side effects like neurotoxicity or worsen kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cancer Pain chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PAIN HYDROMORPHONE USE RENAL INSUFFICIENCY CHRONIC

Contacts and locations

Locations

Tai'an Caner Hospital

Tai’an, Shandong, 271000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.